We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+55.49%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$355M
AUM Growth
+$139M
Cap. Flow
+$59.2M
Cap. Flow %
16.67%
Top 10 Hldgs %
32.72%
Holding
89
New
23
Increased
24
Reduced
19
Closed
10

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$11.2M
2
EW icon
Edwards Lifesciences
EW
+$8.53M
3
DHR icon
Danaher
DHR
+$8.09M
4
ABBV icon
AbbVie
ABBV
+$6.6M
5
CTLT
CATALENT, INC.
CTLT
+$6.45M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$7.1M
2
VRTX icon
Vertex Pharmaceuticals
VRTX
+$6.19M
3
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
+$4.77M
4
ISRG icon
Intuitive Surgical
ISRG
+$4.49M
5
SDGR icon
Schrodinger
SDGR
+$3.79M

Sector Composition

Rank Sector Weight
1 Healthcare 89.79%
2 Technology 0.89%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NBIX icon
1
Neurocrine Biosciences
NBIX
$16.6B
$14.8M 4.18%
121,526
-7,000
-5% -$774K
GWPH
2
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$14.7M 4.14%
119,778
-3,000
-2% -$340K
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$14.6M 4.1%
261,906
+15,000
+6% +$642K
DXCM icon
4
DexCom
DXCM
$32B
$13.2M 3.72%
130,240
+2,108
+2% +$189K
GNMK
5
DELISTED
GenMark Diagnostics, Inc
GNMK
$11.8M 3.32%
800,000
+600,000
+300% +$6.1M
HUM icon
6
Humana
HUM
$46.2B
$11.6M 3.28%
+30,000
New +$11.2M
MRK icon
7
Merck
MRK
$318B
$9.73M 2.74%
131,866
-94,320
-42% -$7.1M
DHR icon
8
Danaher
DHR
$144B
$8.84M 2.49%
+56,400
New +$8.09M
AXNX
9
DELISTED
Axonics, Inc. Common Stock
AXNX
$8.49M 2.39%
241,909
– –
UNH icon
10
UnitedHealth
UNH
$370B
$8.41M 2.37%
28,500
-6,500
-19% -$1.86M
XBI icon
11
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$8.4M 2.37%
+75,000
New +$7.39M
EW icon
12
Edwards Lifesciences
EW
$51.7B
$8.29M 2.34%
+120,000
New +$8.53M
DRNA
13
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$7.64M 2.15%
300,805
– –
NTRA icon
14
Natera
NTRA
$46.4B
$7.49M 2.11%
150,133
+65,000
+76% +$2.61M
XENE icon
15
Xenon Pharmaceuticals
XENE
$6.12B
$7.4M 2.09%
590,267
– –
ABBV icon
16
AbbVie
ABBV
$435B
$7.36M 2.07%
+75,000
New +$6.6M
ICAD
17
DELISTED
iCAD Inc
ICAD
$7.25M 2.04%
725,590
– –
TPTX
18
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$7.13M 2.01%
110,318
+30,000
+37% +$1.73M
CRL icon
19
Charles River Laboratories
CRL
$12.8B
$6.97M 1.96%
+40,000
New +$6.38M
CTLT
20
DELISTED
CATALENT, INC.
CTLT
$6.96M 1.96%
+95,000
New +$6.45M
IQV icon
21
IQVIA
IQV
$39.3B
$6.74M 1.9%
47,500
+17,500
+58% +$2.37M
VCEL icon
22
Vericel Corp
VCEL
$2.31B
$6.57M 1.85%
475,296
+145,000
+44% +$1.96M
KRMD icon
23
KORU Medical Systems
KRMD
$164M
$6.48M 1.83%
721,985
+150,000
+26% +$1.52M
SGEN
24
DELISTED
Seagen Inc. Common Stock
SGEN
$6.37M 1.8%
37,500
+2,390
+7% +$357K
MRSN
25
DELISTED
Mersana Therapeutics
MRSN
$5.85M 1.65%
+10,000
New +$3.41M
1
2 3 4

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Parkman Healthcare Partners held 89 positions worth $355M, up 64% from $216M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Parkman Healthcare Partners deployed $59.2M of net new capital in Q2 2020, opening 23 new positions and adding to 24 existing holdings. Its largest new stake was Humana: 30,000 shares worth $11.6M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 93% a quarter earlier, followed by Technology and Industrials.

On the sell side, the largest reduction was Merck, an estimated $7.1M trimmed.

  • Parkman Healthcare Partners's largest Q2 2020 buy was Humana: 30,000 shares worth $11.6M.
  • Parkman Healthcare Partners added most to GenMark Diagnostics, Inc in Q2 2020, an estimated $6.1M increase.
  • Parkman Healthcare Partners's biggest Q2 2020 reduction was Merck, cutting an estimated $7.1M.
  • Parkman Healthcare Partners fully exited Momenta Pharmaceuticals, Inc. in Q2 2020, selling an estimated $4.77M.
  • Parkman Healthcare Partners's ten largest holdings make up 33% of its $355M portfolio in Q2 2020.
  • Parkman Healthcare Partners opened 23 new positions and closed 10 in Q2 2020.
  • Parkman Healthcare Partners's portfolio value rose 64% quarter-over-quarter to $355M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2020, filed 13 Aug 2020.